C12N 2710/24034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/24034 (Use of virus or viral component as vaccine) appears on 49 US grants and 68 published applications in this corpus.
Search patents in C12N- Granted patents
- 49
- Published applications
- 68
- Assignees
- 46
- Inventors
- 140
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 2 | 2 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 3 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 4 |
| 2011 | 0 | 3 |
| 2012 | 1 | 0 |
| 2013 | 1 | 2 |
| 2014 | 5 | 3 |
| 2015 | 0 | 3 |
| 2016 | 1 | 4 |
| 2017 | 4 | 8 |
| 2018 | 3 | 6 |
| 2019 | 4 | 1 |
| 2020 | 3 | 1 |
| 2021 | 6 | 9 |
| 2022 | 2 | 3 |
| 2023 | 2 | 4 |
| 2024 | 4 | 2 |
| 2025 | 4 | 0 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Conditions improving poxvirus stability9 Jun 2026US 12,648,992 B2Bavarian Nordic A/S
- Serum-free medium for avian vaccine production and uses thereof14 Oct 2025US 12,441,989 B2Boehringer Ingelheim Vetmedica GmbH
- Synthetic chimeric poxviruses22 Jul 2025US 12,365,879 B2Tonix Pharma Limited
- Prostate neoantigens and their uses13 May 2025US 12,295,997 B2Janssen Biotech, Inc.
- Vaccine delivery method7 Jan 2025US 12,186,390 B2University of Georgia Research Foundation, Inc.
- Multi-antigen chimeric vaccine against poxvirus and use thereof20 Aug 2026US 2026/0240989 A1Institute of Microbiology, Chinese Academy of Sciences
- Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox18 Jun 2026US 2026/0166138 A1Yale University
- Synthetic chimeric poxviruses21 May 2026US 2026/0139233 A1Tonix Pharma Limited
- Nucleic acid-based universal vaccine and methods of use thereof14 May 2026US 2026/0130985 A1
- Synthetic chimeric poxviruses22 Jan 2026US 2026/0022350 A1Tonix Pharma Limited
Most cited
By later US patents
- Compositions and methods to enhance the immune system75US 9,352,037 B2Stichting Sanquin Bloedvoorziening · 2016
- Compositions and methods to enhance the immune system42US 8,728,476 B2Stichting Sanquin Bloedvoorziening · 2014
- Nucleic acid and polypeptide sequences useful as adjuvants24US 6,752,995 B2Board of Regents, The University of Texas System · 2004
- Compositions and methods to enhance the immune system18US 9,790,275 B2Stichting Sanquin Bloedvoorziening · 2017
- Compositions and methods to enhance the immune system16US 9,920,122 B2Stichting Sanquin Bloedvoorziening · 2018